ZYIL1 stands out to be a novel oral small molecule NLRP3 inhibitor candidate which is expected to be used for treatment of multiple sclerosis, IBD, and Sepsis.
Amidst the ongoing clinical trial approvals season, Zydus Cadila- one of India’s leading pharmaceutical brand- has recently announced receiving nod from DCGI (Drugs Controller General of India) to commence first phase of clinical trial of ZYIL1 molecule; designated for application as an inhibitor for ‘NLRP3’.
As per official sources, Zydus Cadila had in a regulatory filing stated that the company had received permission to initiate the Phase 1 trial of a novel molecule- ZYIL1 for NLRP3 inhibition.
For the record, these inflammasomes are involved in the inflammation process and it has been aptly claimed that harmful inflammations within the body can lead to the onset and development of various kinds of diseases such as cardiovascular diseases, Acute Respiratory Distress Syndrome, inflammatory diseases, metabolic disorders, auto-immune ailments, and others.
Commenting on the recent approval, the Chairman of Cadila Healthcare- Pankaj R Patel quoted that the company is looking forward to examining the tolerability, safety, pharmacodynamics, and pharmacokinetics of the novel molecule ZYIL1 in the Phase 1 clinical trial in healthy human volunteers. He further added that Cadila is committed to developing such pioneering novel treatments for patients in need.
It was reported that the company had in November 2020, filed the investigational new drug application for ZYIL1, focused on the management of critically ill coronavirus patients.
Post announcement of this major step, the share of Cadila Healthcare rose 1.85% higher at Rs. 479.70 per piece on BSE.
About Zydus Cadila
Headquartered in Ahmedabad, Gujarat, Zydus Cadila stands to be a classic pioneer in the Indian pharmaceutical industry. The company is well acclaimed for its position of being fully integrated global healthcare provider with an in-depth domain expertise in field of healthcare and its robust capabilities across the gamut of pharmaceutical value chain.